Home » Stocks » VIR

Vir Biotechnology, Inc. (VIR)

Stock Price: $36.89 USD -0.46 (-1.23%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 4.80B
Revenue (ttm) 72.63M
Net Income (ttm) -390.34M
Shares Out 130.04M
EPS (ttm) -3.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $36.89
Previous Close $37.35
Change ($) -0.46
Change (%) -1.23%
Day's Open 37.35
Day's Range 36.10 - 37.41
Day's Volume 458,161
52-Week Range 25.31 - 141.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter end...

2 days ago - GlobeNewsWire

Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.

1 week ago - Zacks Investment Research

Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with chronic hepatitis B virus (HBV) infecti...

1 week ago - Benzinga

Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.

Other stocks mentioned: ABBV, AZN, LLY, REGN
3 weeks ago - The Motley Fool

The sample size was small, but the results were impressive.

Other stocks mentioned: GSK
3 weeks ago - The Motley Fool

Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.  The re...

4 weeks ago - Benzinga

– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel  HBV therapies administrated as monotherapy or in combination with other agents –

4 weeks ago - GlobeNewsWire

Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make b...

Other stocks mentioned: AFRM, GSK
1 month ago - Zacks Investment Research

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients with mi...

Other stocks mentioned: GSK
1 month ago - Benzinga

– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces  hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk  of progression ...

1 month ago - GlobeNewsWire

Coronavirus players may deliver strong returns well into the future.

Other stocks mentioned: GRTS, RDHL
1 month ago - The Motley Fool

– Company to host conference call and webcast on Friday, June 25, 2021 at 11:00 AM ET – – Company to host conference call and webcast on Friday, June 25, 2021 at 11:00 AM ET –

1 month ago - GlobeNewsWire

SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at...

1 month ago - GlobeNewsWire

Vir's antibody treatment is addressing one of the biggest COVID challenges.

1 month ago - The Motley Fool

FDA approves Vir Biotechnology antibody drug for emergencies

YouTube video

George Scangos, President and CEO of Vir Biotechnology, joined Yahoo Finance's Julia LaRoche and Adam Shapiro to discuss the latest on the company's COVID-19 antibody treatment. Watch the 2021 Berkshire...

1 month ago - Yahoo Finance

GlaxoSmithKline and Vir Biotechnology won FDA authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. The post The Surprising Move Vir Stock Made After Winning Covid Drug Autho...

Other stocks mentioned: GSK
1 month ago - Investors Business Daily

Vir Biotechnology Inc (NASDAQ: VIR) shares jumped roughly 10% in after-hours trading on Wednesday as the company received emergency use authorisation for its COVID-19 drug from the U.S Food and Drug Adm...

1 month ago - Invezz

The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline Plc (NYSE: GSK) for treating mild-to-moderate C...

1 month ago - Benzinga

– Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk  adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial –

1 month ago - GlobeNewsWire

The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.

Other stocks mentioned: GSK
2 months ago - Zacks Investment Research

The European Medicines Agency's advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) antibody COVID-1...

Other stocks mentioned: GSK
2 months ago - Benzinga

– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –

2 months ago - GlobeNewsWire

– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –

2 months ago - GlobeNewsWire

– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 –

2 months ago - GlobeNewsWire

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter end...

3 months ago - GlobeNewsWire

Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination wi...

Other stocks mentioned: VBIV
3 months ago - Benzinga

DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that ...

Other stocks mentioned: VBIV
3 months ago - Business Wire

Vir is developing treatments in billion-dollar markets.

3 months ago - The Motley Fool

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

Other stocks mentioned: GSK
3 months ago - Zacks Investment Research

GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19 GSK and Vir continue discussions with global regulators to make VIR-7831 available to patient...

3 months ago - GlobeNewsWire

One of the three clearly has the most upside potential.

Other stocks mentioned: GSK, LLY
3 months ago - The Motley Fool

– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations –

3 months ago - GlobeNewsWire

Which stock has more potential for growth over the next year? Let's look to the stars for an answer.

Other stocks mentioned: SRNE
3 months ago - The Motley Fool

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat a...

3 months ago - GlobeNewsWire

Vir Biotechnology Inc (NASDAQ: VIR) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibody main...

3 months ago - Benzinga

– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern –

3 months ago - GlobeNewsWire

Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-admi...

Other stocks mentioned: LLY
3 months ago - Benzinga

INDIANAPOLIS and SAN FRANCISCO and LONDON, March 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced...

Other stocks mentioned: LLY
3 months ago - PRNewsWire

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investi...

Other stocks mentioned: GSK
3 months ago - Benzinga

GlaxoSmithKline and Vir Biotechnology applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

Other stocks mentioned: GSK
3 months ago - CNBC

LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S. Fo...

3 months ago - GlobeNewsWire

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advised to co...

4 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are...

4 months ago - Newsfile Corp

Short-term investors may not see the long-term potential.

Other stocks mentioned: IBB, NVAX, OCGN, XBI
4 months ago - The Motley Fool

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR).  Such investors are advised to c...

4 months ago - PRNewsWire

Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GSK4182136)....

Other stocks mentioned: ALNY
4 months ago - Benzinga

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are...

4 months ago - Newsfile Corp

Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor...

4 months ago - Zacks Investment Research

About VIR

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Bri... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2019
Stock Exchange
NASDAQ
Ticker Symbol
VIR
Full Company Profile

Financial Performance

In 2020, VIR's revenue was $76.37 million, an increase of 843.86% compared to the previous year's $8.09 million. Losses were -$298.67 million, 71.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is 81.17, which is an increase of 120.03% from the latest price.

Price Target
$81.17
(120.03% upside)
Analyst Consensus: Buy